Clinical trial

JAK Inhibitor Dose TAPering Strategy Study

NCT06687551

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2025-06-06

PhasePHASE4

Study timeline

Study start (actual)2025-06-06Date precision: day

Registry last updated2026-08-07

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Rheumatoid Arthritis (RAunresolved

Interventions

Baricitinib (LY3009104) 4 mgDRUG

filgotinib 200mg/dayDRUG

Tofacitinib 5 mg twice dailyDRUG

Upadacitinib 15 MGDRUG

Baricitinib (LY3009104) 4 mgDRUG

filgotinib 200mg/dayDRUG

Tofacitinib 5 mg twice dailyDRUG

Upadacitinib 15 MGDRUG

Sponsors & collaborators

University Hospital, Toulouselead sponsor

Mapped research locations

ParisFrance6 MarseilleFrance1 MontpellierFrance1 StrasbourgFrance1 LilleFrance1 BordeauxFrance1 NiceFrance1 Clermont-FerrandFrance1 RouenFrance1 BrestFrance1 ReimsFrance1 ToursFrance1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06687551 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.